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INTRODUCTION
South Africa’s national antiretroviral therapy (ART) program, launched in 2004, is the
world’s largest [1], with 1.8 million individuals initiated on ART by mid-2011 [2]. Initially,
the threshold for ART eligibility in the national guidelines for adult ART initiation was set
at a CD4 cell count below 200 cells/μl or a WHO Stage IV clinical condition [3]. In late
2009, the WHO revised their guidelines by increasing the threshold for eligibility for ART
in resource-limited settings to ≤350 cells/μl [4,5]. In August 2011, South Africa officially
adopted this policy [6]. It has been estimated that this policy expanded eligibility to an
additional 1.06 million (95%CI: 0.88–1.29m) ART-naïve adults with CD4 values 200–349
cells/μl [2].
Patients who initiate ART with a CD4 above 200 cells/μl are at reduced risk of death and
serious opportunistic infections including tuberculosis, as demonstrated in developed
countries [7–9], a randomized trial in Haiti [10], and observational studies in sub-Saharan
Africa [11–14]. However, if patients initiate treatment before perceiving the clinical
necessity, gains from positive clinical outcomes from earlier treatment may be offset by
increases in patient loss to follow-up [15]. To date, only one study has reported the effect of
initiation at higher CD4 counts on loss to follow-up under routine early initiation (≤350
cells/μl) within sub-Saharan Africa and found 39% reduced loss among those initiating at
CD4 cell counts >200 cells/μl versus ≤200 cells/μl (aHR 0.61, 95%CI: 0.43–0.87) [11].
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Witkoppen Health and Welfare Centre (Witkoppen) is an NGO-operated clinic serving a
primarily poor population from formal and informal settlements in northern Johannesburg,
South Africa. In March 2010, a year before the national policy was enacted, Witkoppen
began ART initiation for all adult patients at the higher threshold of ≤350 cells/μl. This
provides a unique opportunity to examine the impact of initiating treatment among patients
presenting at higher CD4 counts on patient loss to follow-up under routine care.
METHODS
We created a retrospective cohort of all adult (≥18 years) ART-naïve patients initiating ART
at Witkoppen during April-December 2010 who presented with a baseline CD4 value
eligible for ART (≤350 cells/μl). We excluded 29 patients missing a baseline CD4 value,
leaving 1430 for analysis. Data were extracted from the clinic’s electronic patient record
system (TherapyEdge-HIV™) in May 2012, allowing all subjects time to experience a 12-
month outcome. Clinic visits following ART initiation typically are scheduled monthly until
the patient is considered stable and adherent (usually 5–6 months after initiation), at which
time patients may be asked to return every three to six months. Patients who provided a
South African ID number (n=685, 47.9%) were matched to the National Population Register
of the South African Department of Home Affairs in August 2011 to identify deaths. We
conducted a sensitivity analysis restricted only to patients with a valid South African ID
number but this did not change the size of our effect or our conclusions.
We sought to estimate the effect of initiating ART with a CD4 count 201–350 versus ≤200
cells/μl on loss to follow-up (primary outcome) in the first 12 months after ART initiation.
We defined loss to follow-up as not returning to the clinic within 3 months of the patient’s
last missed scheduled visit. For loss to follow-up, person-time began accumulating three
months after ART initiation (when patients became at risk for loss) and excluded 50 patients
who died or transferred in the first three months. Person-time ended at death within 12
months, or the earliest of 12 months of follow-up, loss to follow-up or transfer. For
outcomes of death and incident TB, person-time began accumulating at ART initiation. We
defined baseline CD4 count (≤200 and 201–350 cells/μl) as the temporally last measure
between six months prior and seven days after ART initiation and grouped patients into
those who presented and initiated ART with a lower (≤200 cells/μl) or higher (201–350
cells/μl) baseline CD4 value.
We produced crude Kaplan-Meier curves of time to loss by CD4 group. We used Cox
proportional hazards regression to estimate the association of CD4 category and 12-month
loss to follow-up and report adjusted hazard ratios (aHR) and 95% confidence intervals
(95%CI). We also evaluated the impact of death on estimates of loss using a competing risks
analysis and report the subdistribution hazard ratio (sHR) and 95%CI.
We identified pregnancy at ART initiation as an effect measure modifier of the relation
between CD4 count and loss to follow-up by stratifying estimates of the risk of loss by CD4
group, gender and pregnancy. Based on prior knowledge and change-in-estimate evaluation,
we adjusted models for age, nationality, employment and prevalent TB. The study was
approved by institutional review boards at the University of North Carolina at Chapel Hill
and the University of the Witwatersrand.
RESULTS
Among the 1430 patients, nearly half (48.0%) presented with a CD4 201–350 cells/μl at
ART initiation (Web Appendix 1). Median (IQR) baseline CD4 by group was 105 cells/μl
(55–154) versus 268 cells/μl (239–307). The higher CD4 count group was more likely to be
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<30 years old (31.7% vs. 24.5%) and female (75.7% vs. 63.4%), partly because there were
more pregnant women (19.2% vs. 10.6%) in the higher CD4 group due to routine antenatal
HIV testing. The low CD4 count group had more tuberculosis at ART initiation (16.7% vs.
5.7%).
Within one year of ART initiation, 15.5% (95%CI: 13.0–18.2%) versus 12.7% (95%CI:
10.3–15.3%) were lost among those in the lower versus the higher CD4 group, respectively
(Figure 1). Among non-pregnant females, we found a 42% reduction in loss to follow-up
among women initiating ART at higher versus lower CD4 cell counts (aHR 0.58; 95%CI:
0.37–0.91) (Table 1). Males who initiated ART at higher CD4 counts were also at reduced
risk of loss to follow-up compared to males who started ART at CD4 count ≤200 cells/μl
(aHR 0.74; 95%CI: 0.44–1.23). However among pregnant women there was no association
between CD4 category and loss to follow-up (aHR 0.95; 95%CI: 0.55–1.67). Additionally,
younger adults (age 18–29 years) were 38% more likely to become lost to follow-up
compared to adults age 30–39 years (aHR 1.38, 95%CI: 1.00–1.92), and unemployed
patients were 51% (aHR 1.51, 95%CI: 1.34–2.00) more likely to become lost to follow-up.
Estimates differed little when accounting for death as a competing risk. Figure 1 shows the
gender variation in loss to follow-up: males were more likely to be lost than non-pregnant
females and women pregnant at ART initiation were most likely to be lost.
During the first year of ART care, 29 patients (1.9%; 95%CI: 1.3–2.7%) died and 44
acquired TB (3.1%; 95%CI: 2.3–4.1%). Patients initiating ART at CD4 values 201–350
cells/μl were at much lower risk of death (aHR 0.34; 95%CI: 0.13–0.84) and incident TB
(aHR 0.44; 95%CI: 0.23–0.85) than those with CD4 ≤200 cells/μl.
DISCUSSION
This is the first study from a routine clinical setting in South Africa to demonstrate patients
can be initiated on ART at higher CD4 counts without increasing patient attrition. We found
42% (aHR 0.58; 95%CI: 0.37–0.91) reduced risk of loss to follow-up among non-pregnant
females and 26% (aHR 0.74; 95%CI: 0.44–1.23) reduced risk among male patients who
initiated ART at CD4 counts 201–350 cells/μl compared to those ≤200 cells/μl. This result
is in concert with a 39% reduced loss among those initiating at CD4 cell counts >200 cells/
μl versus ≤200 in Lesotho [11]. However our study highlights substantial variation by
gender in reduced risk at initiating at higher CD4 cell counts. The association of initiating at
higher CD4 counts was greatest among non-pregnant females and males, and null among
pregnant women. Patient loss is a major challenge to providing effective HIV care and our
results suggest that expanding ART eligibility to patients with higher baseline CD4 values
can be done without increasing loss.
We found that loss to follow-up among males of both CD4 groups was substantially higher
than non-pregnant females who initiate at CD4 201–350 cells/μl (Figure 1). Previous studies
also have noted higher loss among men, [16–18] which suggests the need for specific
retention interventions targeted to males. Loss to follow-up among women pregnant at ART
initiation was the highest of any gender group, but interestingly, baseline CD4 did not
substantially affect loss among pregnant women, possibly because loss was already so high.
High loss to follow-up among pregnant women recently has been reported in other studies
within South Africa [19–21], and is particularly concerning since HIV is the largest cause of
maternal mortality in South Africa [22].
Additionally, our results confirm the considerable reductions in mortality and incident
tuberculosis throughout the first year of ART seen among patients who present for care and
initiate ART with a higher CD4 count versus those who present with advanced
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immunosuppression. These findings correspond with those of several studies in resource-
limited settings that observed significantly reduced risk of death and opportunistic infections
when initiating treatment at higher CD4 values [10–14] and support South Africa’s decision
to revise its ART guidelines in 2011 to align with WHO recommendations.
Our study has several strengths. The unique study site allowed us to examine the impact of
initiating at higher CD4 values within the context of routine, clinical care. Additionally, our
analysis assessed the potential for the competing risk of death to bias our associations, but
found little evidence of an important influence. We reduced the likelihood of death being
misclassified as loss to follow-up by validating deaths using South Africa’s national death
registry and conducting a sensitivity analysis of our primary outcome. However, the registry
only includes patients with a valid South African ID number (47.9%) and included only
deaths through data export in August 2011, thus it is possible that our estimate of mortality –
particularly among patients lacking an ID number – may be underestimated.
Limitations to our analysis include use of data obtained from a single site and therefore
findings may not be generalizable to all public-sector settings within South Africa or health
care centers in other regions. As with most retention studies, we cannot know if a patient
continued care at another facility due to unlinked data at facilities. Thus, loss to follow-up in
this study must be understood as lost to the facility where ART was initiated. It is important
not to interpret our results as evidence for when to start ART (i.e. a comparison of whether
or not to initiate patients when their CD4 count first falls ≤350 or defer until CD4 counts
reach <200). Our results only pertain to what happens to patients once they are diagnosed
and initiate ART at their initial presentation CD4 value.
Our results show that adult, non-pregnant patients presenting for care and initiating ART at
201–350 cells/μl have reduced loss to follow-up than those presenting and initiating ART at
≤200 cells/μl, with significant variation by gender and pregnancy status. These are the first
results to show South Africa’s 2011 expansion of ART treatment guidelines can be enacted
without increasing attrition among patients initiating at higher CD4 values. As data become
available from more sites that adopted the policy of initiating ART at higher CD4 cell
counts, it will be important to perform similar evaluations at other sites in South Africa and
other countries. Such information will be invaluable to national HIV/AIDS programs
looking for guidance about the implications of earlier ART initiation, and may inform future
expansions of the ART treatment criteria in South Africa.
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Web Appendix Table 1. Characteristics of the study participants by
baseline CD4 group
Patient characteristic Total (N=1430)





 Female 991 (69.3) 471 (63.4) 520 (75.7)
 Male 439 (30.7) 272 (36.6) 167 (24.3)
Age at HIV testing, median (IQR) 34.3 (29.3, 41.2) 35.2 (30.0, 42.2) 33.3 (28.7, 39.9)
Age at HIV testing, n (%)
 18–29 years 400 (28.0) 182 (24.5) 218 (31.7)
 30–39 years 625 (43.7) 327 (44.0) 298 (43.4)
 40 years and older 405 (28.3) 234 (31.5) 171 (24.9)
First CD4 value (cells/mm3), median
(IQR)
195 (103, 266) 105 (55, 154) 268 (239, 307)
First CD4 value, n (%)
 <50 cells/μl 169 (11.8) 169 (22.8) 0 (0.0)
 50–100 cells/μl 182 (12.7) 182 (24.5) 0 (0.0)
 101–200 cells/μl 392 (27.4) 392 (52.8) 0 (0.0)
 201–350 cells/μl 687 (48.0) 0 (0.0) 687 (100.0)
Nationality, n (%)
 Born in South Africa 969 (67.8) 504 (67.8) 465 (67.7)
 Born outside of South Africa 461 (32.2) 239 (32.2) 222 (32.3)
Employment status, n (%)
 Employed 736 (51.5) 391 (52.6) 345 (50.2)
 Not employed 694 (48.5) 352 (47.4) 342 (49.8)
TB at ART initiation, n (%)
 No 1267 (88.6) 619 (83.3) 648 (94.3)
 Yes 163 (11.4) 124 (16.7) 39 (5.7)
Pregnant at ART initiation, n (%)
 No 1219 (85.2) 664 (89.4) 555 (80.8)
 Yes 211 (14.8) 79 (10.6) 132 (19.2)
IQR, interquartile range
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Figure 1. Kaplan-Meier estimates of time to loss to follow-up by baseline CD4 value (top) and by
baseline CD4 by gender/pregnancy at ART initiation status (bottom)
Note that the y-axes range from 0.7 to 1.0. Loss to follow-up is defined as not returning ≥3
months after the last scheduled visit; thus, person-time begins accumulating at 3 months.
CLOUSE et al. Page 7

























CLOUSE et al. Page 8
Table 1
Multivariate analysis of factors associated with patient loss to follow-up after ART initiation at an HIV
treatment program in South Africa (N=1430).
n (%) Crude HR (95% CI) Adjusted HR (95% CI)
Competing risk sHR*
(95% CI)
Non-pregnant female, CD4 ≤200 cells/μl 50/369 (13.6) 1 1 1
Non-pregnant female, CD4 201–350
cells/μl
33/380 (8.7) 0.61 (0.39, 0.94) 0.58 (0.37, 0.91) 0.59 (0.38, 0.91)
Male, CD4 ≤200 cells/μl 45/261 (17.2) 1 1 1
Male, CD4 201–350 cells/μl 22/164 (13.4) 0.74 (0.44, 1.23) 0.74 (0.44, 1.23) 0.74 (0.45, 1.24)
Pregnant at ART initiation, CD4 ≤200
cells/μl
20/76 (26.3) 1 1 1
Pregnant at ART initiation, CD4 201–
350 cells/μl
32/130 (24.6) 0.93 (0.53, 1.62) 0.95 (0.55, 1.67) 0.96 (0.56, 1.67)
Age at HIV testing
 18–29 years 74/383 (19.3) 1.50 (1.10, 2.06) 1.38 (1.00, 1.92) 1.39 (1.00, 1.91)
 30–39 years 83/605 (13.7) 1 1 1
 40 years and older 45/392 (11.5) 0.83 (0.58, 1.20) 0.93 (0.64, 1.35) 0.93 (0.64, 1.34)
Nationality
 Born in South Africa 139/931 (14.9) 1 1 1
 Born outside of South Africa 63/449 (14.0) 0.95 (0.70, 1.27) 0.82 (0.61, 1.11) 0.83 (0.61, 1.12)
Employment status
 Employed 87/716 (12.2) 1 1 1
 Unemployed 115/664 (17.3) 1.50 (1.14, 1.99) 1.51 (1.34, 2.00) 1.50 (1.13, 1.99)
TB at ART initiation
 Yes 22/155 (14.2) 0.97 (0.63, 1.52) 1.01 (0.64, 1.59) 1.00 (0.63, 1.59)
 No 180/1225 (14.7) 1 1 1
HR, hazard ratio; CI, confidence interval; n (%) show proportion lost to follow-up in each category
Models are adjusted for all variables listed
Loss to follow-up is defined as not returning ≥3 months after the last scheduled visit; the HR models exclude 50 patients who died or transferred
prior to 3 months follow-up (N=1380)
*
The competing risk subdistribution hazard ratio (sHR) model includes all 1430 patients and assesses patient loss to follow-up in the presence of
the competing risk of death
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